• 1
    Ulmer, J. B., Wahren, B. and Liu, M. A., Gene-based vaccines: recent technical and clinical advances. Trends Mol. Med. 2006. 12: 216222.
  • 2
    Dhama, K., Mahendran, M., Gupta, P. K. and Rai, A., DNA vaccines and their applications in veterinary practice: current perspectives. Vet. Res. Commun. 2008. 32: 341356.
  • 3
    Klinman, D. M., CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines 2003. 2: 305315.
  • 4
    Petrovsky, N. and Aguilar, J. C., Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 2004. 82: 488496.
    Direct Link:
  • 5
    Liu, M. A., Wahren, B. and Karlsson Hedestam, G. B., DNA vaccines: recent developments and future possibilities. Hum. Gene Ther. 2006. 17: 10511061.
  • 6
    Lu, S., Wang, S. and Grimes-Serrano, J. M., Current progress of DNA vaccine studies in humans. Expert Rev. Vaccines 2008. 7: 175191.
  • 7
    Sato, Y., Roman, M., Tighe, H., Lee, D., Corr, M., Nguyen, M. D., Silverman, G. J. et al., Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996. 273: 352354.
  • 8
    Klinman, D. M., Yamshchikov, G. and Ishigatsubo, Y., Contribution of CpG motifs to the immunogenicity of DNA vaccines. J. Immunol. 1997. 158: 36353639.
  • 9
    Krieg, A. M., Wu, T., Weeratna, R., Efler, S. M., Love-Homan, L., Yang, L., Yi, A. et al., Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl. Acad. Sci. U S A 1998. 95: 1263112636.
  • 10
    Coban, C., Ishii, K. J., Gursel, M., Klinman, D. M. and Kumar, N., Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors. J. Leukoc. Biol. 2005. 78: 647655.
  • 11
    Gursel, M., Verthelyi, D., Gursel, I., Ishii, K. J. and Klinman, D. M., Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J. Leukoc. Biol. 2002. 71: 813820.
  • 12
    Klinman, D. M., Currie, D., Gursel, I. and Verthelyi, D., Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 2004. 199: 201216.
  • 13
    Liu, Y., Luo, X., Yang, C., Yu, S. and Xu, H., Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice. Vaccine 2011. 29: 57785784.
  • 14
    Hartmann, G., Battiany, J., Poeck, H., Wagner, M., Kerkmann, M., Lubenow, N., Rothenfusser, S. et al., Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur. J. Immunol. 2003. 33: 16331641.
  • 15
    Roman, M., Martin-Orozco, E., Goodman, J. S., Nguyen, M. D., Sato, Y., Ronaghy, A., Kornbluth, R. S. et al., Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 1997. 3: 849854.
  • 16
    Klinman, D. M., Barnhart, K. M. and Conover, J., CpG motifs as immune adjuvants. Vaccine 1999. 17: 1925.
  • 17
    Pontarollo, R. A., Babiuk, L. A., Hecker, R. and Van Drunen Littel-Van Den Hurk, S., Augmentation of cellular immune responses to bovine herpesvirus-1 glycoprotein D by vaccination with CpG-enhanced plasmid vectors. J. Gen. Virol. 2002. 83: 29732981.
  • 18
    Rodriguez, E. G., Vazquez, D. M., Herrera, A. M. and Duarte, C. A., Enhanced cell-mediated IFN-gamma-secreting activity against the HIV-1IIIB V3 peptide of the TAB9 multiepitope after DNA vaccine backbone engineering. Biochem. Biophys. Res. Commun. 2003. 308: 713718.
  • 19
    Schneeberger, A., Wagner, C., Zemann, A., Luhrs, P., Kutil, R., Goos, M., Stingl, G. et al., CpG motifs are efficient adjuvants for DNA cancer vaccines. J. Invest. Dermatol. 2004. 123: 371379.
  • 20
    Zhang, A., Jin, H., Zhang, F., Ma, Z., Tu, Y., Ren, Z., Zhang, X. et al., Effects of multiple copies of CpG on DNA vaccination. DNA Cell. Biol. 2005. 24: 292298.
  • 21
    Chen, Y. S., Hsiao, Y. S., Lin, H. H., Liu, Y. and Chen, Y. L., CpG-modified plasmid DNA encoding flagellin improves immunogenicity and provides protection against Burkholderia pseudomallei infection in BALB/c mice. Infect. Immun. 2006. 74: 16991705.
  • 22
    Vollmer, J., Weeratna, R., Payette, P., Jurk, M., Schetter, C., Laucht, M., Wader, T. et al., Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 2004. 34: 251262.
  • 23
    Marshall, J. D., Fearon, K., Abbate, C., Subramanian, S., Yee, P., Gregorio, J., Coffman, R. L. and Van Nest, G., Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J. Leukoc. Biol. 2003. 73: 781792.
  • 24
    Krieg, A. M., CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002. 20: 709760.
  • 25
    Chaung, H. C., CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy. Int Immunopharmacol 2006. 6: 15861596.
  • 26
    Verthelyi, D., Ishii, K. J., Gursel, M., Takeshita, F. and Klinman, D. M., Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J. Immunol. 2001. 166: 23722377.
  • 27
    Bernasconi, N. L., Onai, N. and Lanzavecchia, A., A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003. 101: 45004504.
  • 28
    Shoda, L. K., Kegerreis, K. A., Suarez, C. E., Mwangi, W., Knowles, D. P. and Brown, W. C., Immunostimulatory CpG-modified plasmid DNA enhances IL-12, TNF-alpha, and NO production by bovine macrophages. J. Leukoc. Biol. 2001. 70: 103112.
  • 29
    Oehen, S., Junt, T., Lopez-Macias, C. and Kramps, T. A., Antiviral protection after DNA vaccination is short lived and not enhanced by CpG DNA. Immunology 2000. 99: 163169.
  • 30
    Cornelie, S., Poulain-Godefroy, O., Lund, C., Vendeville, C., Ban, E., Capron, M. and Riveau, G., Methylated CpG-containing plasmid activates the immune system. Scand. J. Immunol. 2004. 59: 143151.
  • 31
    Verfaillie, T., Cox, E. and Goddeeris, B. M., Immunostimulatory capacity of DNA vaccine vectors in porcine PBMC: a specific role for CpG-motifs? Vet. Immunol. Immunopathol. 2005. 103: 141151.
  • 32
    Kojima, Y., Xin, K. Q., Ooki, T., Hamajima, K., Oikawa, T., Shinoda, K., Ozaki, T. et al., Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine. Vaccine 2002. 20: 28572865.
  • 33
    Leitner, W. W., Ying, H., Driver, D. A., Dubensky, T. W. and Restifo, N. P., Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res. 2000. 60: 5155.
  • 34
    Kirman, J. R., Turon, T., Su, H., Li, A., Kraus, C., Polo, J. M., Belisle, J. et al., Enhanced immunogenicity to mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. Infect. Immun. 2003. 71: 575579.
  • 35
    Nordstrom, E. K., Forsell, M. N., Barnfield, C., Bonin, E., Hanke, T., Sundstrom, M., Karlsson, G. B. and Liljestrom, P., Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1. J. Gen. Virol. 2005. 86: 349354.
  • 36
    Yu, Y. Z., Zhang, S. M., Sun, Z. W., Wang, S. and Yu, W. Y., Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A. Vaccine 2007. 25: 88438850.
  • 37
    Yu, Y., Yu, J., Li, N., Wang, S., Yu, W. and Sun, Z., Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors. Vaccine 2009. 27: 61486153.
  • 38
    Leitner, W. W., Hwang, L. N., deVeer, M. J., Zhou, A., Silverman, R. H., Williams, B. R., Dubensky, T. W. et al., Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med. 2003. 9: 3339.
  • 39
    Leitner, W. W., Hwang, L. N., Bergmann-Leitner, E. S., Finkelstein, S. E., Frank, S. and Restifo, N. P., Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine 2004. 22: 15371544.
  • 40
    Leitner, W. W., Bergmann-Leitner, E. S., Hwang, L. N. and Restifo, N. P., Type I Interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine 2006. 24: 51105118.
  • 41
    Zhang, Y., Qiu, J., Zhou, Y., Farhangfar, F., Hester, J., Lin, A. Y. and Decker, W. K., Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses. Vaccine 2008. 26: 614622.
  • 42
    Midha, S. and Bhatnagar, R., Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses. Eur. J. Immunol. 2009. 39: 159177.
  • 43
    Hoene, V., Peiser, M. and Wanner, R., Human monocyte-derived dendritic cells express TLR9 and react directly to the CpG-A oligonucleotide D19. J. Leukoc. Biol. 2006. 80: 13281336.
  • 44
    Rynkiewicz, D., Rathkopf, M., Sim, I., Waytes, A. T., Hopkins, R. J., Giri, L., DeMuria, D. et al., Marked enhancement of the immune response to BioThrax(R) (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers. Vaccine 2011. 29: 63136320.
  • 45
    Yu, Y. Z., Li, N., Wang, W. B., Wang, S., Ma, Y., Yu, W. Y. and Sun, Z. W., Distinct immune responses of recombinant plasmid DNA replicon vaccines expressing two types of antigens with or without signal sequences. Vaccine 2010. 28: 75297535.
  • 46
    Yu, Y. Z., Li, N., Zhu, H. Q., Wang, R. L., Du, Y., Wang, S., Yu, W. Y. et al., The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate. Vaccine 2009. 27: 28162822.